CheckMate 9UT trial: what clinicians have said so far
A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without Bacillus Calumette-Guerin (BCG) in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
- NCT03519256 ↗
- Terminated
- Bristol-Myers Squibb
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on CheckMate 9UT (nivolumab; nivolumab plus BCG; nivolumab plus linrodostat (BMS-986205) in BCG-unresponsive high-risk non-muscle invasive bladder cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CheckMate 9UT so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab/BMS-986205 Alone or Combined With Intravesical BCG in Participants With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Urinary Bladder Neoplasms
- Interventions
- Nivolumab; BCG; BMS-986205
- Arms
- Nivolumab monotherapy · Experimental
- Nivolumab + BCG · Experimental
- Nivolumab + BMS-986205 · Experimental
- Nivolumab + BMS-986205 + BCG · Experimental
- Enrollment
- 142
- Primary outcomes
- Number of Participants With Adverse Events (AEs)
- Number of Participants With Serious Adverse Events (SAEs)
- Number of Participants With Adverse Events (AEs) Leading to Discontinuation of Study Treatment
- Number of Participants Immune-Mediated Adverse Events (IMAEs)
- Number of Participants Who Died
- Number of Participants With Specific Liver Laboratory Abnormalities
- Number of Participants With Specific Thyroid Laboratory Abnormalities
- Number of Participants With Changes From Baseline Laboratory Values
- Number of Participants With Adverse Events (AEs) by Anti-Drug- Antibody (ADA) Status
- Number of Participants With Serious Adverse Events (SAEs) by Anti-Drug- Antibody (ADA) Status
- Sponsor
- Bristol-Myers Squibb
- Start
- Aug 2, 2018
- Primary completion
- Aug 22, 2022
- Results posted
- Yes
- Registry record
- NCT03519256 · updated Jun 1, 2023